KPCB helped add $35m to a round for the immunotherapy developer featuring Gilead Sciences, Ping An, Be The Match BioTherapies and Eli Lilly.
US-based immunotherapy developer Tmunity Therapeutics increased a series A round backed by several corporates to $135m yesterday, after raising $35m from venture capital firm Kleiner Perkins Caufield and Byers (KPCB) and unnamed affiliates.
Tmunity secured an initial $100m in January 2018 from investors including biopharmaceutical company Gilead Sciences, insurance provider Ping An, pharmaceutical firm Eli Lilly and cellular researcher Be The Match BioTherapies.
University of Pennsylvania and Parker Institute for Cancer Immunotherapy also took part in the January close.…